Navigation Links
Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
Date:10/30/2008

SUNNYVALE, Calif., Oct. 30 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results for its first fiscal quarter ended September 30, 2008. The net loss for the first quarter of fiscal 2009, was $6.5 million, or $0.25 per share, compared to a net loss of $6.8 million, or $0.26 per share, in the first quarter of fiscal 2008.

Total operating expenses were $6.6 million in the first quarter of fiscal 2009, including $1.4 million of severance related share-based compensation expense and $0.5 million of severance expense. Excluding the $1.9 million of severance related share-based compensation and severance expenses, total expenses were $4.7 million in the first quarter of fiscal 2009 compared to $7.3 million for the first quarter of fiscal 2008, a decrease of $2.6 million. Excluding $1.4 million in severance related share-based compensation expense, share-based compensation expense was $0.4 million in the first quarter of fiscal 2009 compared to $0.7 million in the first quarter of fiscal 2008. The decrease of $2.6 million in total operating expenses, after excluding the severance related expenses, in the first quarter of fiscal 2009 was primarily due to reduced personnel expenses due to lower headcount and reduced manufacturing costs and outside preclinical expenses associated with the company's HDAC, Btk and Factor VIIa inhibitor programs.

As of September 30, 2008, the company's cash, cash equivalents and marketable securities totaled $12.5 million compared to $16.8 million at June 30, 2008.

Robert W. Duggan stated, "Entering my second month as Chairman and Interim CEO, there are a few observations I wish to share with my fellow stakeholders. Pharmacyclics is a company consisting of hi
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
2. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
3. Pharmacyclics Announces It Received Nasdaq Notification
4. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
5. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
6. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
7. United Therapeutics Reports Third Quarter 2008 Financial Results
8. BioMed Realty Trust Reports Third Quarter 2008 Financial Results
9. Varian, Inc. Reports Strong Fourth Quarter 2008 Results
10. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
11. VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... According to a new market report published by Transparency ... valued at USD 3,754.6 million in 2012 and is estimated ... CAGR of 5.9% from 2013 to 2019. , Nearly half ... by bone and joint disorders, and this number is expected ... will continue to increase the demand for orthobiologics. Other factors ...
(Date:8/29/2014)... 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the ... results for the six months ended June 30, ... Canadian dollars and presented under International Financial Reporting ... , Announced top-line results related to ... for subjects enrolled in the Phase 2 iDEAL ...
(Date:8/29/2014)... Livermore, California (PRWEB) August 29, 2014 ... Department of Energy's 2014 Hydrogen Production R&D ... photoelectrochemically -- by splitting water using sunlight. , ... Laboratory (NREL) and the University of Nevada, Las ... its work developing models of photoelectrochemical solar-hydrogen production ...
(Date:8/29/2014)... Boston, MA (PRWEB) August 29, 2014 ... ones in the biotech start-up dense realm of Boston-Cambridge, ... alliances and able investors. James Sherley, the Director of ... made increasing the local and national visibility of his ... in September 2013. , In addition to a social ...
Breaking Biology Technology:Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Livermore Team Awarded for Hydrogen Production Research 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4
... - Engineers at the University of Idaho have developed ... NASA missions that will study the Earth and Sun-Earth ... grant technical officer Pen-Shu Yeh, a senior engineer at ... team at the University of Idaho,s (U-Idaho) ...
... A high-end skin care brand from Dermaheal now available in the ... to customers, doorsteps with biweekly home delivery. , ... ... Miracle skin care program, an organic, preservative-free product ...
... CAMBRIDGE, Mass. -- A new type of highly sensitive ... expand the limits of modern biomedical imaging, allowing scientists ... in living cells and tissues without the use of ... on stimulated Raman scattering (SRS), works by detecting the ...
Cached Biology Technology:New one-of-a-kind technology will fly on 2 NASA missions 2New one-of-a-kind technology will fly on 2 NASA missions 3Organic, Preservative-Free Skin Care Products from Dermaheal Now Available in the United States 2Organic, Preservative-Free Skin Care Products from Dermaheal Now Available in the United States 3New label-free method tracks molecules and drugs in live cells 2
(Date:8/31/2014)... busy attacking us, germs go after each other. But ... for the infected microbes: Sometimes viruses actually carry helpful ... its diet or better attack its own hosts. , ... system would robotically destroy anything it recognized as invading ... now revealed that one variety of the bacterial immune ...
(Date:8/29/2014)... Davis have made some surprising discoveries about the ... immunodeficiency virus (SIV), the team found that specialized ... early responders to viral invasion and are the ... called interleukin-1 beta (IL-1β). , Though aimed ... of the gut epithelium that provides a barrier ...
(Date:8/29/2014)... the type and number of connections in transcription factor ... robustness in a study published in PLOS Computational ... the assortativity signature contributes to a network,s resilience against ... the out-out assortativity of TFN models has a greater ... three types of assortativity," said Dov A. Pechenick, PhD, ...
Breaking Biology News(10 mins):Discovery reveals how bacteria distinguish harmful vs. helpful viruses 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 3The early cost of HIV 2Assortativity signatures of transcription factor networks contribute to robustness 2
... patients diagnosed with peripheral neuropathy had lower medical ... treated with a folate-enriched prescription medical food, according ... for Pharmacoeconomics and Outcomes Research 12th Annual European ... study, funded by Pamlab, L.L.C., which manufactures the ...
... blood cells, which make up 45 percent of blood, normally ... either side. But they can sometimes deform into an asymmetrical ... to explore how fluid flow might be responsible for this ... blood flow. The insights could help understand the mechanisms involved ...
... with researchers at four other institutions to explore ... under a five-year, $15.2 million award from the ... Center was launched Oct. 26 as one of ... Physical Sciences-Oncology Centers. Collaborating with Princeton will be: ...
Cached Biology News:Medical food reduces medical costs and use of anti-convulsant medication 2NCI awards $15.2 million to create Princeton Physical Sciences -- Oncology Center 2NCI awards $15.2 million to create Princeton Physical Sciences -- Oncology Center 3NCI awards $15.2 million to create Princeton Physical Sciences -- Oncology Center 4
...
Practical tool for easy, effective sealing of 0.2ml PCR tubes and plates using cap strips....
Kit for testing the ability of a compound to simulate lipolysis in cultured human adipocytes. Kit contains controls, buffers and reagents for detecting glycerol and non-esterified free fatty acids. A...
... Telomerase Detection Kit is a ... for the fluorometric detection and ... activity. It incorporates refinements to ... adds the ability to quantitate ...
Biology Products: